A B A B RTPS MLC 3 強 度 変 調 放 射 線 治 療 (intensity-modulated radiation therapy : IMRT) IMRT D CRT X D CRT IMRT OAR D CRT OAR IMRT MLC X MLC MLC IMRT D CR
|
|
|
- あまめ かやぬま
- 9 years ago
- Views:
Transcription
1 総 説 小 動 物 臨 床 関 連 部 門 Radiation therapy for cancer: current status and future directions in veterinary medicine Takashi MORI Faculty of Applied Biological Sciences, Gifu University, 1 1 Yanagido, Gifu, , Japan 1 は じ め に 2 3 次 元 原 体 照 射 (three-dimensional conformal radiation therapy : 3D-CRT) X D CRT CT CT D CRT X multi-leaf collimator : MLC CT radiation treatment planning system : RTPS CT organ at risk : OAR X CT OAR forward planning FAX [email protected] Correspondence to : Takashi MORI (Faculty of Applied Biological Sciences, Gifu University) 1 1 Yanagido, Gifu, , Japan TEL FAX [email protected] 173
2 A B A B RTPS MLC 3 強 度 変 調 放 射 線 治 療 (intensity-modulated radiation therapy : IMRT) IMRT D CRT X D CRT IMRT OAR D CRT OAR IMRT MLC X MLC MLC IMRT D CRT OAR RTPS X inverse planning IMRT 174
3 IMRT stereotactic radiotherapy : SRT STI 4 画 像 誘 導 放 射 線 治 療 (image-guided radiation therapy : IGRT) IMRT volume effect OAR SRT SRT IGRT X CT RTPS 6 化 学 放 射 線 療 法 (chemoradiotherapy) IGRT inter-fractional motion intra-fractional motion inter-fractional motion intrafractional motion intra-fractional motion 5 定 位 放 射 線 治 療 (stereotactic irradiation : STI) STI mm EGFR stereotactic radiosurgery : SRS EGFR 175
4 8 大 線 量 小 分 割 照 射 の 問 題 X, VEGFR VEGFR 7 空 間 的 分 割 グリッド 照 射 (spatially fractionated GRID radiation therapy : SFGRT) SFGRT, SFGRT TNF TGF SFGRT dose escalation LQ LQ in vitro Gy, in vivo LQ 9 人 材 及 びコスト 面 の 問 題 IMRT IGRT 引 用 文 献 Takahashi S : Conformation radiotherapy. Rotation techniques as applied to radiography and radiotherapy of cancer, Acta Radiol Diagn (Stockh), Suppl 176
5 : + Farrelly J, McEntee MC : A Survey of Veterinary Radiation Facilities in, Vet Radiol Ultrasound, in press. Covey JL, Farese JP, Bacon NJ, Schallberger SP, Amsellem P, Cavanaugh RP, Milner RJ : Stereotactic radiosurgery and fracture fixation in dogs with appendicular osteosarcoma, Vet Surg,, Mariani CL, Schubert TA, House RA, Wong MA, Hopkins AL, Barnes Heller HL, Milner RJ, Lester NV, Lurie DM, Rajon DA, Friedman WA, Bova FJ : Frameless stereotactic radiosurgery for the treatment of primary intracranial tumours in dogs, Vet Comp Oncol Nolan MW, Griffin LR, Custis JT, LaRue SM : Stereotactic body radiation therapy for treatment of injection-site sarcomas in cats: cases ( ), J Am Vet Med Assoc,, Fidel J, Lyons J, Tripp C, Houston R, Wheeler B, Ruiz A : Treatment of oral squamous cell carcinoma with accelerated radiation therapy and concomitant carboplatin in cats, J Vet Intern Med,, Marconato L, Nitzl DB, Melzer-Ruess KJ, Keller MA, Buchholz J : Chemotherapy and radiation therapy in dogs with muscle-invasive transitional cell carcinoma of the urinary tract, Can Vet J,, Williams LE, Pruitt AF, Thrall DE : Chemotherapy followed by abdominal cavity irradiation for feline lymphoblastic lymphoma, Vet Radiol Ultrasound,, Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK : Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: -year survival data from a phase randomised trial, and relation between cetuximabinduced rash and survival, Lancet Oncol,, Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS : Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG, J Clin Oncol Jakob J, Rauch G, Wenz F, Hohenberger P : Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma, BMJ Open,, e Barney BM, Markovic SN, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, Bauer HJ, Olivier KR : Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT), Int J Radiat Oncol Biol Phys,, Mangoni M, Vozenin MC, Biti G, Deutsch E : Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead, Br J Cancer,, Buckey C, Stathakis S, Cashon K, Gutierrez A, Esquivel C, Shi C, Papanikolaou N : Evaluation of a commercially-available block for spatially fractionated radiation therapy, J Appl Clin Med Phys,, Neuner G, Mohiuddin MM, Vander Walde N, Goloubeva O, Ha J, Yu CX, Regine WF : High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT, Int J Radiat Oncol Biol Phys,, Penagaricano JA, Griffin R, Corry P, Moros E, Yan Y, Ratanatharathorn V : Spatially fractionated (GRID) therapy for large and bulky tumors, J Ark Med Soc,, Park C, Papiez L, Zhang S, Story M, Timmerman RD : Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy, Int J Radiat Oncol Biol Phys,, Guerrero M, Li XA : Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy, Phys Med Biol,, 177
1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
untitled
260 250 200 150 10 100 50 0 1960 1965 1970 1975 1980 1985 1985 1995 2000 2005 25% 56% 66% 60% 90 80 70 60 50 40 30 20 10 0 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 1999 1990 2003 2005 2010 500,000 70,000 100,000
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
PowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
分子標的薬アプデート 2018
Primary imatinib, 2002-2008 (CML IV) 5-year survival 93% n = 2830 Survival probability IFN or SCT, 1997-2008 (CML IIIA) 5-year survival 71% IFN or SCT, 1995-2008 (CML III) 5-year survival 63% IFN, 1986-2003
H + e - X (
がん放射線治療 基礎的知識から最新の治療まで H + e - X ( X X Linear accelerator 金属 電子線 4 10MV 深部の腫瘍に届く 皮膚が焼けにくい 100% 50% 6MV X 100% 2 6 8 10 12cm 120KV X 表面より奥が最大になる 50% 9MeV 2 6 8cm 皮膚が焼けにくい 皮膚上にボーラスをのせる 2Gy x 5 回 / 週 月火水木金
北陸地域アイソトープ研究会誌第7号
IMRT Hyper-radiosensitivity and Increased radioresistance Radiation adaptive response Radiation-induced bystander effect 0.5 Gy hyper-radiosennsitivity HRS 0.5 Gy increased radioresistance IRR HRS IRR
20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
indd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
化学療法剤の適切な使い方について
1 2 3 4 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, 1988 8 Cancer: Principles & Practice of Oncology
PowerPoint Presentation
Glioma 28% astrocytoma (WHO I) 0.28 anaplastic (WHO II/III) 0.18 Glioblastoma (WHO IV) 0.32 others 0.22 Meningioma partly malignant) 26% Pituitary adenoma 17% Neurinoma 11% Craniopharyngioma etc 5% Others
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 3 8 ...2...2...2...2...3...4...4...5...9...9...9...9...9... 13... 13... 13... 13... 13... 13... 13... 14... 14... 15... 15... 15...
胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
1.放射線治療概論
to 56 1981 18 2006 32 9,314 10 261.0 30.4 1981 cancer,carcinoma sarcoma T3 T2 T1 M1 N 1 N2 N3 M1 DIC DNA 10 9 65% 25% 3 65 1.29 1.29 2.07 QOL quality of life 17 19.6% 1 4 27 25.2% 1 3 62 32.3%
1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y)
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 1 1977 x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y) ( x 2 y + xy 2 x 2 2xy y 2) = 15 (x y) (x + y) (xy
52-2.indb
Jpn. J. Health Phys., 52 (2) 55 60 (2017) DOI: 10.5453/jhps.52.55 * 1 * 2 * 2 * 3 * 3 2016 10 28 2017 3 8 Enhancement of Knowledge on Radiation Risk Yukihiko KASAI,* 1 Hiromi KUDO,* 2 Masahiro HOSODA,*
日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
付表-放射線治療計画ガイドライン.indd
70 Gy 60 Gy 55 Gy 70 Gy 壊死, 潰瘍脳 神付表 1. 通常分割照射における正常組織の耐容線量 ( 小児については 小児 総論 (p. 250) を参照のこと) 注意 :(1) 本表で示される耐容線量はあくまでも臨床経験 (2 Gy 前後の 1 回線量を用いクラークソン等の線量計算 ) を元にした参考値に過ぎず, 合併症が起こらないことを保証する線量ではない 現在, 原著報告時と異なり,
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11
1-122013 1 2 1 2 20 2,000 2009 12 1 2 1,362 68.1 2009 1 1 9.5 1 2.2 3.6 0.82.9 1.0 0.2 2 4 3 1 2 4 3 Key words acupuncture and moxibustion Treatment with acupuncture, moxibustion and Anma-Massage-Shiatsu
9.プレゼン資料(小泉)R1
1 Me-DigIT 2 TRO, TMECH Interesting Readings IJMRCAS, TUFFC The Most 3., etc.. etc.. etc. 4 TRO09 5 J TRO09 The Most Interesting Readings J http://www.learner.org/interactives/renaissance/printing.html
Fig. 1 Method of SRCA Table 1 Drug dose and treatment schedule in SRCA Table 2 Results of SRCA for renal cell carcinomas * Histological grading of the
SUBRENAL CAPSULE ASSAY FOR CHEMOSENSITIVITY TEST OF URINARY TRUCT CANCERS Jun Hasegawa, Yoshio Yamanaka, Kezutaka Horiuchi and Masao Akimoto Department of Urology, Nippon Medical School (Director: Prof.
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
Understanding Stem Cell Transplant 2007
Understanding Stem Cell Transplant IMF International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
1) Delbet P: Retrocissement du choledoque. Cholecysto-duodenostomie. Bull Mem Soc Nat Chir 50: 1144-1146, 1924 2) Wiesner RH, LaRusso NF: Clinicopathologic Features of the Syndrome of Primary Sclerosing
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%
住まい・まちづくり活動事例集
3 H15 1982 1988 5 H16.31 1 1 1 246 26 3 2003 11 21,417/ 65 17.91% 16.62%1.29 246 2 1 12 1246 5008026 30080 3 200803 120060 2 20013 1 1 21 11 19821988 199112003 13 1988 1 1991 28 3 1991 1993 1992 1 1995
MV X 5 6 Common Terminology Criteria for Adverse Events Grade 1 Grade Gy 16 QOL QOL 5 6 7, 8 9, VOL.3 NO
乳がん患者の放射線皮膚炎に対するスキンケアの指導の実際 がん放射線療法看護認定看護師とがん放射線治療に携わる看護師との比較 Educating practice of skin care for radiodermatitis of breast cancer patients: Comparison of the nurses with certified nurse in radiation therapy
理学療法検査技術習得に向けた客観的臨床能力試験(OSCE)の試行
An Application of an Objective Structured Clinical Examination for Learning Skills in Assessment of Physical Therapy A Task Involving Measurements on the Range of Motion Test Chikako Fujita1) Hiroyasu
03J_sources.key
Radiation Detection & Measurement (1) (2) (3) (4)1 MeV ( ) 10 9 m 10 7 m 10 10 m < 10 18 m X 10 15 m 10 15 m ......... (isotope)...... (isotone)......... (isobar) 1 1 1 0 1 2 1 2 3 99.985% 0.015% ~0% E
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
Single slice helical CT CT 1 2005 1 4 1. CT Anti-Lung Cancer Association: ALCA 1-5) 1993 9 10 ALCA (Nawa 6) ) single slice helical CT 10mm CT 2. 1 (http://www.thoracic-ctscreening.org/jpn/index.html )
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
1) Perissat J, Collet DR, Belliard R : Gallstones ; laparoscopic treatment, intracorporeal lithotripsy followed by cholecystotomy on cholecystectomy. Endoscopy 21 : 373-374, 1989 2) Kato K, Matsuda M,
Unknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.3, No.3 July 2014 Original Article Clinical significance of classification of mixed-pattern tumor by breast ultrasound...
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
原 著 放射線皮膚炎に対する保湿クリームの効果 耳鼻科領域の頭頸部照射の患者に保湿クリームを使用して * 要旨 Gy Key words はじめに 1 70Gy 2 2 QOL
原 著 放射線皮膚炎に対する保湿クリームの効果 耳鼻科領域の頭頸部照射の患者に保湿クリームを使用して * 1 2 1 2 要旨 2011 1 2013 9 33 0 1 6 16 17 60Gy Key words はじめに 1 70Gy 2 2 QOL 3 4 2014 6 16 2015 4 17 連絡先 359 0042 3 2 Phone 04 2995 1511 Fax 04 2995 0633
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
教育講演 放射線治療における位置的不確かさの影響 ずれるとどうなる 都島放射線科クリニック / 大阪大学塩見浩也 放射線治療を確実に施行するためには, 安全なマージンの設定が不可欠である. ターゲットの設定は,ICRU report 50, 62 3) で規定されている肉眼的腫瘍体積 (GTV; g
教育講演 放射線治療における位置的不確かさの影響 ずれるとどうなる 都島放射線科クリニック / 大阪大学塩見浩也 放射線治療を確実に施行するためには, 安全なマージンの設定が不可欠である. ターゲットの設定は,ICRU report 50, 62 3) で規定されている肉眼的腫瘍体積 (GTV; gross tumor volume), 臨床標的体積 (CTV; clinical target volume),itv(internal
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
J. Jpn. Stomatol. Soc. 39(1) : , January, 1990 Clinical and histopathological studies of combination therapy with Cisplatin and Peplomycin (PP t
J. Jpn. Stomatol. Soc. 39(1) : 175183, January, 1990 Clinical and histopathological studies of combination therapy with Cisplatin and Peplomycin (PP therapy) for the carcinoma of the tongue Iwai TOHNAI,
前頭蓋底の再建術式の標準化と外傷への応用
52 4 226 234 2009 watertight watertight 53 5 temporal musculo pericranial flap frontal musculo pericranial flap 1984 5 5 60 1 2 3 2 8 38 226 52 4 1 2/3 1 2 3 50 905 912 2007 7 3 1 A B C 2 loose areolar
ACTIVE FOCUS
ACTIVE FOCUS Am ACTIVE FOCUS 100% ACTIVE FOCUS 1, m x 4 10-3* 0-4 -4 -.5 x 10-3* 4 0 - - -1.5-1 ACTIVEFOCUS -0.5 0 0.5 mm 1 1.5.5 69.4 1 40.5 100 1, -4 -.5 - -1.5-1 -0.5 0 0.5 mm 1 1.5.5 CPD AcyrSof IQ
untitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- [email protected] http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
jsfm_著者紹介_160520
Sarah M. A. Caney 1 European Journal of Companion Animal Practice (2015) Autumn 25 (3) EJCAP 25(3) Special issue 2015 P4 Commissioned paper* Management of the elderly cat Sarah M. A. Caney 1-01 - EJCAP
案内最終.indd
1 2 3 4 5 6 IC IC R22 IC IC http://www.gifu-u.ac.jp/view.rbz?cd=393 JR JR JR JR JR 7 / JR IC km IC km IC IC km 8 F HPhttp://www.made.gifu-u.ac.jp/~vlbi/index.html 9 Q01a N01a X01a K01a S01a T01a Q02a N02a
1) K. J. Laidler, "Reaction Kinetics", Vol. II, Pergamon Press, New York (1963) Chap. 1 ; P. G. Ashmore, "Catalysis and Inhibition of Chemical Reactio
1) K. J. Laidler, "Reaction Kinetics", Vol. II, Pergamon Press, New York (1963) Chap. 1 ; P. G. Ashmore, "Catalysis and Inhibition of Chemical Reactions", Butterworths, London (1963) Chap. 7, p. 185. 2)
EVALUATION OF MAGNETIC RESONANCE IMAGING (MRI) IN DIAGNOSIS OF ACOUSTIC NEUROMA-COMPARATIVE STUDY WITH PLAIN X-RAY AND CTS- KIMIHISA NOMURA, M.D., MAK
EVALUATION OF MAGNETIC RESONANCE IMAGING (MRI) IN DIAGNOSIS OF ACOUSTIC NEUROMA-COMPARATIVE STUDY WITH PLAIN X-RAY AND CTS- KIMIHISA NOMURA, M.D., MAKOTO SAKAI, M.D., ATSUSHI SHINKAWA, M.D. and HIROSATO
Unknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ
E82/E87/E88 BMW Brake Pad Matching List GLAD Model Model No. Year Front Rear etc 116i UF16 / UE F#148 R# i UF F#148 R#
E82/E87/E88 No. Year Front Rear etc 116i UF16 / UE16 04-11 F#148 R#146 118i UF18 04-11 F#148 R#146 04-06 F#145 UF20 120i 06-07 F#148 R#146 UD20 07-11 F#187 120i Coupe / Cabriolet UC20 / UL20 08-11 F#187
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
